Odronextamab Monotherapy Appears Safe, Effective in R/R DLBCL With Progression After CAR-T
In patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) with disease progression after chimeric antigen receptor T-cell (CAR-T) therapy ...
Anxiety, Depression Elevated in Patients with Histiocytic Neoplasms
While previous research has documented high levels of anxiety and depression in patients with cancer, mood disorders have not been systematically studied in patients ...
Ibrutinib-Rituximab Outperforms Chemotherapy in Front-Line MCL, Trial Finds
Treating patients with mantle cell lymphoma (MCL) with a front-line regimen of ibrutinib and rituximab (IR) produced better progression-free survival (PFS) than the pooled ...
Quadruple Combination with Brentuximab Vedotin, Nivolumab Continues to Show Strong Efficacy in Early-Stage cHL
The quadruple combination of brentuximab vedotin (BV), nivolumab, doxorubicin, and dacarbazine showed a high and durable complete response rate (CRR) in patients with early-stage ....
Patients in R/R Marginal Zone Lymphoma Cohort of ELM-2 Show Superior Outcomes With Odronextamab
Odronextamab showed good clinical efficacy and a generally manageable safety profile in heavily pretreated patients with relapsed or refractory (R/R) marginal zone lymphoma ...
Bispecific T-Cell Engager Results in CR, Clears MRD in Patients with R/R Follicular Lymphoma
Patients with heavily pretreated relapsed or refractory (R/R) follicular lymphoma (FL) treated with AZD0486, a bispecific T-cell engager, had a high response rate ...
BOVen Regimen NCCN-Approved Option for TP53-Mutated MCL
The three-drug regimen of zanubrutinib, obinutuzumab, and venetoclax — dubbed the BOVen regimen — is an effective option for patients with TP53-mutated mantle cell lymphoma ...
Etoposide Safe to Combine With Brentuximab Vedotin, Results in High CRR in PTCL
In patients with CD30-positve peripheral T-cell lymphoma (PTCL), treatment with cyclophosphamide, doxorubicin, prednisone, brentuximab vedotin, and etoposide (CHEP-BV) ...
LBCL Treated With CAR-T Therapy Can Have Durable Responses to Subsequent CAR-T Treatment
Patients with large B-cell lymphoma (LBCL) treated with a CD22-targeted chimeric antigen receptor (CAR) T-cell therapy had durable clinical responses, despite prior disease progression ...
Fully Automated Lugano Response Assessment Achieves High Accuracy in FDG-Avid Non-Hodgkin Lymphoma
A deep learning-based method for fully automated Lugano treatment response assessment in 18F-fluorodeoxyglucose (FDG)–avid non-Hodgkin lymphoma ...
